Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Peptinovo Biopharma, Inc. holds a company patent portfolio with 2 pending office actions. These matters are located in the Biotechnology & Pharmaceuticals technology area. Both actions are concentrated within 1 distinct art unit. This focus on 1 art unit suggests a very specific technical niche within the pharmaceutical sector for the company's current filings.
The prosecution involves 2 distinct examiners for these 2 pending office actions. ESPINOSA, CLAUDIA EDILMA is the busiest examiner, currently managing 1 pending office action. This means the 2 pending actions are split between 2 different examiners despite being in the same art unit. For practitioners, this indicates that while the technical classification is the same, the matters will be subject to the individual review styles of 2 different examiners. The concentration of 2 actions in 1 art unit with 2 examiners shows a high degree of scrutiny within a single technical group.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +56.1% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19204171 | CHEMOTHERAPEUTIC PACLITAXEL BASED MICELLULAR NANOPARTICLES | ESPINOSA, CLAUDIA EDILMA | 73d overdue |
| 17634975 | PALM FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY INCIDENTAL TO THE TREATMENT OF CANCER | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19204171 | CHEMOTHERAPEUTIC PACLITAXEL BASED MICELLULAR NANOPARTICLES | ESPINOSA, CLAUDIA EDILMA | 1654 | §102§103§112DP | Final Rejection | 73d overdue | Pending | May 09, 2025 |
| 17634975 | PALM FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY INCIDENTAL TO THE TREATMENT OF CANCER | DABKOWSKI, ERINNE R | 1654 | DP | Final Rejection | — | Pending | Feb 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPeptinovo Biopharma, Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Claudia Edilma Espinosa has the most, with 1 of Peptinovo Biopharma, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
